Dr Reddy's announces launch of OTC tablets in US market

MUMBAI: Pharma major Dr Reddy's Laboratories today said it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride extended release tablets in the US market.

The company has launched over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride extended release tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D in the US market on November 18, a statement issued here said.

Dr Reddy's ANDA is approved by the United States Food & Drug Administration ( USFDA). The Allegra-D 12 Hour brand has US sales of approximately $49.8 million for the latest 52 weeks ending October 6 for total US multi outlet.

Dr Reddy's Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg is available in a 20 count blister, the release said.

Shares of the company closed marginally up at Rs 3,519.25 on BSE today.